Vivione Biosciences, LLC, the operating subsidiary of PACEpartners Inc. appoints Quip Laboratories as a Distribution Partner

/NOT FOR DISTRIBUTION TO UNITED STATES WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/

CALGARY, July 16, 2013 /CNW/ - PACEpartners Inc. (TSXV:PIA) (PACEpartners) is pleased to announce that its operating subsidiary Vivione Biosciences, LLC (Vivione) has appointed Quip Laboratories (Quip) as a distribution partner in the US and Canada for the seafood and fresh produce food safety markets.

Vivione's RAPID-B system is able to provide pathogen detection down to a single cell in seven hours or less (including sample preparation) versus the 24 hours up to several days that it takes with competitive systems. The rapid time-to-results capability allows food processors to more closely monitor their manufacturing plants, incoming raw materials, as well as mitigate the risk of a food safety recall.

According to Kevin Kuykendall, PACEpartners' CEO: "Quip's excellent customer relationships and their tradition of product innovation over the past 30 years make them a natural distribution partner for the introduction of the RAPID-B system into the seafood and fresh produce markets. Quip has already purchased a RAPID-B system for demonstrations and we look forward to working closely with them over the coming years to introduce this new technology to the market."

According to Tim Hidell, Quip's CEO: "Vivione's RA PID-B platform could revolutionize the produce and seafood diagnostic markets.  RAPID-B's ability to detect a single cell of bacteria in seven hours or less will provide food producers with the ability to reduce chemical costs, reduce inventory hold times, optimize manufacturing efficiencies, and ultimately reduce their product recall risk. We're excited to work with Vivione to introduce this new technology."

About Vivione

Vivione Biosciences, LLC, the operating subsidiary of PACEpartners Inc.(TSXV:PIA), is a life sciences diagnostic company who collaborated with the Food and Drug Administration's National Center for Toxicological Research (NCTR) over six years to develop RAPID-B.  Vivione's RAPID-B system provides for the rapid detection of bacterial pathogens applicable to the food safety, clinical diagnostics and other markets including agricultural, water testing, pharmaceutical, and medical device applications.  Vivione's business is centered on the commercialization of the new ultra high performance RAPID-B, an integrated diagnostic system consisting of hardware, software and wetware that tests bacteria in key environments and provides test results in seven hours or less, including sample preparation. This technology has diverse applicability from food safety to clinical diagnostics by rapidly identifying and quantifying microorganism levels down to a single cell.

About Quip

Since its founding in 1985, Quip Laboratories, Inc. has been devoted to its mission of identifying, creating and delivering innovative technologies that enable the safest and most eco-gentle outcomes for clients across several industry sectors.  Through this singular strategic commitment, Quip Laboratories has set the standards for biosafety and quality.  The company's critical process monitoring programs feature in-line validation, to verify effective cleaning and sanitation.  The company compliments its novel technologies with an array of professional services that clients have come to consider essential adjuncts to their own capabilities.   The company is headquartered in Wilmington, Delaware, and can be found on the web at www.quiplabs.com.  For more information, contact Quip Laboratories at 1-800-424-2436

Cautionary Statements

This news release contains "forward-looking statements" within the meaning of applicable securities laws. Although PACEpartners believes that the expectations reflected in its forward-looking statements are reasonable, such statements have been based on factors and assumptions concerning future events that may prove to be inaccurate. These factors and assumptions are based upon currently available information to PACEpartners. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. Readers are cautioned to not place undue reliance on forward-looking statements. The statements in this press release are made as of the date of this release and, except as required by applicable law, PACEpartners does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. PACEpartners undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of PACEpartners, Vivione or its financial or operating results or (as applicable), their securities.

The securities mentioned herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.  This press release does not constitute an offer to sell or the solicitation of any offer to buy these securities in any jurisdiction.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICE PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: PACEpartners Inc.

PACEpartners Inc.      
Kevin Kuykendall
Chief Executive Officer
Tel: [phone]
[email protected]
www.vivionebiosciences.com

Quip Laboratories, Inc.
Tim Hidell
Chief Executive Officer
Tel: [phone]
www.quiplabs.com